TABLE 7.

Hazard ratios (HR) for progression-free survival in the population with an intermediate/poor prognosis.

		Intervention [HR (95% CI)]
		CAB + NIV	AXY + PEM	LEN + PEM	NIV + IPI	SUN
Comparator	CAB + NIV		1.48 (0.75; 2.31)	0.80 (0.39; 1.26)	1.61 (0.83; 2.50)	2.19 (1.19; 3.35)
	AXY + PEM	0.73 (0.38; 1.14)		0.54 (0.38; 0.73)	1.10 (0.82; 1.39)	1.50 (1.22; 1.79)
	LEN + PEM	1.37 (0.67; 2.18)	1.89 (1.32; 2.53)		2.06 (1.43; 2.71)	2.80 (2.09; 3.54)
	NIV + IPI	0.67 (0.35; 1.04)	0.93 (0.69; 1.17)	0.50 (0.35; 0.66)		1.38 (1.13; 1.62)
	SUN	0.49 (0.26; 0.74)	0.67 (0.55; 0.81)	0.36 (0.27; 0.46)	0.73 (0.60; 0.86)

The values in each cell represent the relative treatment effect for the intervention on the top when compared to the intervention on the left. Green suggests a relative treatment benefit (light green a nonsignificant benefit, and dark green a significant benefit). Red suggests a relative treatment harm (light red a nonsignificant harm, and dark red a significant harm).AXY, axitinib; CAB, cabozantinib; IPI, ipilimumab; LEN, lenvatinib; NIV, nivolumab; PEM, pembrolizumab; SUN, sunitinib